These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16960460)

  • 1. Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism.
    Park HC; Choi HY; Kim BS; Kang SW; Choi KH; Ha SK; Lee HY; Han DS
    Kidney Blood Press Res; 2006; 29(4):216-24. PubMed ID: 16960460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status.
    van der Kleij FG; Schmidt A; Navis GJ; Haas M; Yilmaz N; de Jong PE; Mayer G; de Zeeuw D
    Kidney Int Suppl; 1997 Dec; 63():S23-6. PubMed ID: 9407415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of angiotensin-converting enzyme gene polymorphism on proteinuria and arterial hypertension.
    Zivko M; Kusec R; Galesić K
    Coll Antropol; 2013 Sep; 37(3):765-70. PubMed ID: 24308214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of renin-angiotensin system genotypes on the antiproteinuric response to high doses of olmesartan in non-diabetic proteinuric nephropathies.
    Goyache-Goñi B; Aranda-Lara P; Reyes-Engels A; Frutos-Sanz MA; Hernández-Marrero D
    Nefrologia; 2013 Nov; 33(6):771-8. PubMed ID: 24241364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary TGF-beta1 as an indicator of antiproteinuric response to angiotensin II receptor blocker in proteinuric renal diseases.
    Park HC; Choi HY; Kim BS; An HR; Lee JS; Ha SK; Han DS
    Biomed Pharmacother; 2009 Nov; 63(9):672-8. PubMed ID: 19278811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renoprotective efficacy of valsartan in chronic non-diabetic proteinuric nephropathies with renin-angiotensin system gene polymorphisms.
    Lee YJ; Jang HR; Kim SG; Chae DW; Do JY; Lee JE; Huh W; Kim DJ; Oh HY; Kim YG
    Nephrology (Carlton); 2011 Jul; 16(5):502-10. PubMed ID: 21303424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Polymorphism studies of angiotensin converting enzyme gene in chronic glomerulonephritis].
    Kutyrina IM; Tareeva IE; Nosikov VV; Kamyshova ES; Gorashko NM; Chistiakov DA; Okonova EB; Troepol'skaia OV
    Ter Arkh; 1999; 71(6):30-4. PubMed ID: 10420452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacogenetics of angiotensin system in non diabetic nephropathy].
    Coto E; Marín R; Alvarez V; Praga M; Fernández Andrade C; Arias M; Poveda R; Vallés M; Galcerán JM; Luño J; Rivera F; Campistol JM
    Nefrologia; 2005; 25(4):381-6. PubMed ID: 16231503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
    Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS
    Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus.
    Ha SK; Yong Lee S; Su Park H; Ho Shin J; Jung Kim S; Hun Kim D; Rae Kim K; Yung Lee H; Suk Han D
    Nephrol Dial Transplant; 2000 Oct; 15(10):1617-23. PubMed ID: 11007831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
    Russo D; Minutolo R; Pisani A; Esposito R; Signoriello G; Andreucci M; Balletta MM
    Am J Kidney Dis; 2001 Jul; 38(1):18-25. PubMed ID: 11431176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y; Taura K; Taguchi T; Furusu A; Kohno S
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients.
    van der Kleij FG; Navis GJ; Gansevoort RT; Heeg JE; Scheffer H; de Zeeuw D; de Jong PE
    Nephrol Dial Transplant; 1997; 12 Suppl 2():42-6. PubMed ID: 9269699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1.
    Perna A; Ruggenenti P; Testa A; Spoto B; Benini R; Misefari V; Remuzzi G; Zoccali C
    Kidney Int; 2000 Jan; 57(1):274-81. PubMed ID: 10620209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria.
    Ellis D; Vats A; Moritz ML; Reitz S; Grosso MJ; Janosky JE
    J Pediatr; 2003 Jul; 143(1):89-97. PubMed ID: 12915830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
    Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Angiotensin-converting enyme insertion/deletion polymorphism and blood pressure regulation in type 2 diabetic patients].
    Krajina-Andricević M; Zibar L; Glavas-Obrovac- L; Stefanić M; Avdicević M; Barbić J
    Acta Med Croatica; 2011 Oct; 65 Suppl 3():14-9. PubMed ID: 23120809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.
    Jacobsen P; Rossing K; Rossing P; Tarnow L; Mallet C; Poirier O; Cambien F; Parving HH
    Kidney Int; 1998 Apr; 53(4):1002-6. PubMed ID: 9551410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
    Andersen S; Tarnow L; Cambien F; Rossing P; Juhl TR; Deinum J; Parving HH
    Kidney Int; 2002 Jul; 62(1):192-8. PubMed ID: 12081578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.
    Hou FF; Xie D; Zhang X; Chen PY; Zhang WR; Liang M; Guo ZJ; Jiang JP
    J Am Soc Nephrol; 2007 Jun; 18(6):1889-98. PubMed ID: 17494885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.